A small/big step in the nanosafety road

The ever increasing consumption of nano-enabled products and use of nanotechnologies raise a critical question: are we aware of the potential consequences of these products and technologies on human health and ? The NANoREG Project, in which participated, helped to answer this question.

When, in 2011, first met Tom*, it was almost impossible to figure out the unique opportunity for Portugal participation in a European “pioneer” project in nano– NANoREG. At that time, in Portugal, the nano issues were not yet a particular concern, and attentions were mainly focused on the high potential and expectations brought by nanotechnologies developments. However, , always mindful of issues, considered NANoREG a strategic project for the future of nanomaterials and their acceptance by society and, therefore decided to integrate the project.

The project dimension, both in terms of its ambitious objectives, the number and of the participating partners, as well as its strategic importance, offered many opportunities that, if adequately exploited, could increase project impact at national level. This reasoning took to invite three national entities (the National Health Institute Doutor Ricardo Jorge – INSA, the Portuguese General Directorate of Health – DGS, and The Portuguese Institute for – IPQ) to integrate the NANoREG project and this jointly collaboration was called PToNANO, coordinated by . This approach allowed a more active and broad national participation with a higher impact in national economy and society. The PToNANO cooperation by itself was innovative, allowing to share resources, risks and knowledge towards the same goal, the nanomaterials .

Another innovative aspect of NANoREG was its funding model. NANoREG budget overcame 50 million euros, of which 10 million came from UE FP7 funding, and the remaining were provided by private and public financing from the participating EU Member States and countries. In Portugal, almost all financial effort came directly from the 4 participating entities. The European funding requested for Portugal mainly covered travel expenses for project meetings and dissemination, and other communication and dissemination activities.

Within the project, PToNANO carried out a set of actions aiming at identifying the main national actors (i.e., , academy, regulator, among others) working in and the main gaps and needs regarding the al, health and (EHS) aspects related to production, use and end-of-life of nanomaterial, thus leveraging close collaborations with and between interested parties.

Taking advantage of the synergies created along project development, a group of entities promoted the of the national Technical Standardization Committee on (CT 194), which follows and participates on the /TC 229 and CEN/TC 352. The CT194 has been developing an intensive work of evaluating and commenting standards and other normative documents that are being developed within the two above mentioned Committees, and on the translation of published normative documents, considered fundamental for common understanding of nanotechnologies and to facilitate their safer and responsible use.

PToNANO also contributed to the scientific evidence on the potential toxicity of nanomaterials, to the development and validation of testing procedures, and to the development of “new” approaches for the assessment of nanomaterials, such as the “Safe-by-Design” concept.

NANoREG produced a great amount of results integrated in the “ProSafe White Paper”, available by the end of the first semester of 2017, with recommendations for regulators and innovators regarding cost-efficient risk assessment of nanomaterials. The project produced a large set of well-defined experimental nano-EHS data, of great value since the data on exposure and effects can be linked to accurate physicochemical data, which are required to relevant QSAR approaches and in silico studies regarding the toxicological modes of action (MoA) of nanomaterials.

NANoREG partners agreed to make data and project deliverables public available. This make it possible for ongoing (NANoREG2 and caLIBRAte) and future to build on the results of NANoREG.

When, a few days ago, we said goodbye to Tom, after our last project meeting, more than satisfaction for a well done job – that for Portugal represents an important step in the direction towards a safer and more responsible use of nanomaterials – there was the certainty that we are now better prepared to support the national in their development and innovative processes on nanomaterials and nano-enabled products. There was also the conviction that, despite the big steps given by the NANoREG project, these are still small steps in the long way towards the safer development, production and use of nanomaterials.


  1. Providing legislators with a set of tools for risk assessment and decision making instruments for the short to medium term, by gathering data and performing pilot risk assessment, including exposure monitoring and control, for a selected number of nanomaterials used in products;
  2. Developing for the long term, new testing strategies adapted to a high number of nanomaterials where many factors can affect their al and health impact.
  3. Establishing a close collaboration among authorities and with regard to the knowledge required for appropriate risk , and create the basis for common approaches, mutually acceptable datasets and risk practices.


NANoREG is the first European project to deliver the answers needed by regulators and legislators on EHS by linking them to a scientific evaluation of data and test methods.

Based on the scientific evaluation of methods and results, NANoREG contributed to minimize the occupational exposure risks and to introduce in the market nano-enabled products safer for the consumer and the . Thus, it contributes to promote innovation, competitiveness and the responsible development of nanotechnologies.

This project run from March 1, 2013 to February 28, 2017 (48 months), with 87 partners from 19 countries, including Portugal, in the 7th Framework Programme (FP7).  It involved three main stakeholders (Regulation, and Science), whom significantly contributed to reduce the risks from MNMs in industrial and consumer products.


  • More than 50 Million euros
  • 17 European countries + Brazil and South Korea
  • 87 Partners
  • Duration 48 months

By Helena Gouveia, e Nádia Vital, .


O é uma entidade privada e independente com 50 anos de actividade, que presta serviços de inspeção, ensaio, formação e consultoria técnica.

Oferecemos aos nossos clientes serviços e soluções integradas e inovadoras garantindo a conformidade dos seus activos e produtos com as normas e regulamentos em termos de qualidade, segurança, ambiente e responsabilidade social.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply